Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/10/22
Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/15/22
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVenturesGlobeNewsWire • 07/26/22
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)GlobeNewsWire • 07/19/22
How Much Upside is Left in Inozyme Pharma, Inc. (INZY)? Wall Street Analysts Think 309%Zacks Investment Research • 06/24/22
Inozyme Pharma Announces Partnership with Rady Children's Institute for Genomic Medicine to Advance Newborn Screening for Genetic DiseasesGlobeNewsWire • 06/16/22
Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business HighlightsGlobeNewsWire • 05/10/22
Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-MarketGlobeNewsWire • 04/14/22
Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 DeficiencyGlobeNewsWire • 04/12/22
Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/06/22
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 DeficiencyGlobeNewsWire • 04/04/22
Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business HighlightsGlobeNewsWire • 03/15/22
Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 DeficiencyGlobeNewsWire • 11/15/21
Wall Street Analysts Believe Inozyme Pharma, Inc. (INZY) Could Rally 257%: Here's is How to TradeZacks Investment Research • 11/12/21